Group 1 - The company has launched five new drugs by 2024, including its first innovative drug, EGFR-TKI Alectinib (brand name: Kaimena®), ALK inhibitor Ensartinib (brand name: Beimana®), third-generation EGFR inhibitor BPI-D0316 (brand name: Saimena®), and targeted drug Vorolanib (brand name: Fumeina®) [1] - The company is currently reviewing the market application for its new breast cancer drug BPI-16350 (brand name: Kangmeina®) and a strategic collaboration product, which is expected to contribute to new revenue growth in the future [1] - The company has established a robust revenue growth and cash flow through academic promotion, commercial operation, and lifecycle cost control, ensuring a positive cycle of "R&D - commercialization - reinvestment" for orderly advancement of its subsequent R&D pipeline [1] Group 2 - The company's internationalization strategy is accelerating, with the application for Beimana's first-line indication approved by the FDA in December 2024, and the EMA's application process officially initiated [2] - The company invested 717 million yuan in R&D in 2024, accounting for 24.80% of its operating revenue, focusing resources on key R&D projects [2] - Multiple innovative drug INDs have been approved during the reporting period, including BPI-520105 tablets, BPI-221351 tablets, EYP-1901 intravitreal implant, CFT8919 capsules, and BPI-452080 tablets [2]

Group 1 - The actual controller, chairman, and CEO of Juran Smart Home, Wang Linpeng, has been detained, but the company's operations remain normal and unaffected [1] - Juran Smart Home reported a total revenue of 12.966 billion yuan in 2024, a decrease of 4.04% year-on-year, and a net profit of 883 million yuan, down 32.08% year-on-year, primarily due to economic fluctuations and increased competition in the home furnishing market [3][4] Group 2 - China Bank plans to raise up to 165 billion yuan through a private placement of A-shares, with the funds aimed at increasing its core tier one capital [4] - The issuance price for China Bank's shares is set at 6.05 yuan per share, which is 80% of the average trading price over the previous 20 trading days [4] - The Bank of Communications also plans to raise up to 120 billion yuan through a private placement, with the funds also designated for core tier one capital [5] Group 3 - SANY Heavy Industry reported a total revenue of 78.383 billion yuan in 2024, an increase of 5.9% year-on-year, and a net profit of 5.975 billion yuan, up 31.98% year-on-year [6][7] - The company's international main business revenue reached 48.513 billion yuan, accounting for 63.98% of total revenue, with significant growth in various regions [6][8] - SANY Heavy Industry has established 37 lighthouse factories and is recognized for its advanced smart manufacturing capabilities [8] Group 4 - East China Pharmaceutical achieved a total revenue of 41.906 billion yuan in 2024, a growth of 3.16%, and a net profit of 3.512 billion yuan, up 23.72% year-on-year [10][11] - The company has a robust pipeline of over 80 innovative drugs, focusing on diabetes and oncology [11][12] Group 5 - EVE Energy reported a total revenue of 48.615 billion yuan in 2024, a slight decrease of 0.35%, with a net profit of 4.076 billion yuan, an increase of 0.63% [13][14] - The company has seen significant growth in its energy storage business, with a shipment volume of 50.45 GWh, a year-on-year increase of 91.90% [15] Group 6 - China Unicom reported a revenue of 103.35 billion yuan in Q1 2025, a growth of 3.9%, and a net profit of 2.61 billion yuan, up 6.5% year-on-year [19] - Lens Technology achieved a revenue of 17.063 billion yuan in Q1 2025, a growth of 10.10%, with a net profit of 429 million yuan, up 38.71% year-on-year [20] Group 7 - Fuyao Glass reported a revenue of 9.910 billion yuan in Q1 2025, a growth of 12.16%, with a net profit of 2.030 billion yuan, up 46.25% year-on-year [21] - Zhuye Group reported a revenue of 4.803 billion yuan in Q1 2025, a growth of 8.50%, with a net profit of 277 million yuan, up 74.07% year-on-year [23] Group 8 - Cailong Technology reported a net profit growth of 87.55% in 2024, with total revenue of 11.664 billion yuan [32] - Ziyan Food reported a revenue of 3.363 billion yuan in 2024, with a net profit growth of 4.5% [33] Group 9 - Shunyi Environmental reported a revenue of 12.678 billion yuan in 2024, with a net profit growth of 41.58% [35] - Shougang Group turned a profit in Q1 2025, reporting a revenue of 26.533 billion yuan, down 10.18%, with a net profit of 328 million yuan [36] Group 10 - Keda Li reported a revenue of 12.030 billion yuan in 2024, with a net profit growth of 22.55% [38] - Betta Pharmaceuticals reported a revenue of 2.892 billion yuan in 2024, with a net profit growth of 15.67% [40] Group 11 - New Australia reported a revenue of 4.841 billion yuan in 2024, with a net profit growth of 5.96% [41] - Fawer reported a revenue of 16.468 billion yuan in 2024, with a net profit growth of 11.93% [42] Group 12 - Zhongwei Company reported a revenue of 9.065 billion yuan in 2024, with a net profit decrease of 9.53% [43] - Changying Precision reported a revenue of 16.934 billion yuan in 2024, with a net profit growth of 800% [44] Group 13 - Stanley reported a revenue of 10.263 billion yuan in 2024, with a net profit growth of 17.89% [45] - Puyang reported a revenue of 5.192 billion yuan in 2024, with a net profit decrease of 45.48% [46] Group 14 - Huangshi Group received a notice of administrative penalty for failing to disclose significant contracts, with potential fines for the company and responsible individuals [47] - Baosteel announced plans to acquire a 49% stake in Maanshan Steel through a combination of cash purchases and capital increases, with an estimated total investment of 9 billion yuan [48][49] Group 15 - Shengquan Group reported a revenue of 2.459 billion yuan in Q1 2025, with a net profit growth of 50.46% [50]

Core Viewpoint - ICBC Medical Care Stock (000831) has experienced a decline of 0.12% on April 17, with a latest net value of 2.47 yuan, marking a cumulative drop of 1.2% over three consecutive trading days [1] Group 1: Fund Performance - The fund was established in November 2014, with a total scale of 2.644 billion yuan and a cumulative return of 146.70% since inception [1] - As of the end of 2024, institutional investors hold 0.41 million shares, accounting for 3.55% of total shares, while individual investors hold 11.19 million shares, making up 96.45% of total shares [1] Group 2: Fund Management - Current fund manager Zhao Bei has a master's degree and has been with ICBC Credit Suisse since 2010, serving as the fund manager since November 18, 2014 [2] - The current fund manager Ding Yang holds a doctoral degree and joined ICBC Credit Suisse in December 2017, taking over as fund manager on May 5, 2023 [2] Group 3: Portfolio Holdings - As of December 31, 2024, the top ten holdings of ICBC Medical Care Stock account for a total of 36.38%, with major positions including: - Heng Rui Medicine (9.51%) - WuXi AppTec (5.65%) - Mindray Medical (3.83%) - Yuyue Medical (2.88%) - Betta Pharmaceuticals (2.66%) - BeiGene (2.62%) - Aier Eye Hospital (2.41%) - Baiyang Pharmaceutical (2.33%) - Kelun Pharmaceutical (2.30%) - New Horizon Health (2.19%) [3]

Financial Performance - The company's operating revenue for 2024 reached ¥2,891,950,112.03, representing a 17.74% increase compared to ¥2,456,196,486.62 in 2023[16]. - Net profit attributable to shareholders for 2024 was ¥402,569,335.69, up 15.67% from ¥348,032,472.42 in 2023[16]. - The net profit after deducting non-recurring gains and losses was ¥409,834,141.43, a significant increase of 55.92% from ¥262,848,818.84 in 2023[16]. - The company's total assets at the end of 2024 amounted to ¥9,341,677,723.81, reflecting a 2.13% increase from ¥9,146,908,395.53 at the end of 2023[16]. - The weighted average return on equity for 2024 was 7.43%, an increase of 0.54% from 6.89% in 2023[16]. - The company reported a net cash flow from operating activities of ¥911,172,176.22, a slight decrease of 0.33% compared to ¥914,227,977.50 in 2023[16]. - The company achieved a revenue of 289,195.01 million yuan, representing a year-on-year growth of 17.74%[75]. - The net profit attributable to shareholders was 40,256.93 million yuan, an increase of 15.67% compared to the previous year[75]. - The net profit excluding non-recurring gains and losses was 40,983.41 million yuan, reflecting a significant growth of 55.92% year-on-year[75]. Research and Development - The company has established research centers in Beijing and Hangzhou to enhance its drug development capabilities[9]. - The company is focused on developing new drugs, particularly targeting oncology treatments, which are critical for its growth strategy[9]. - The company has launched five new drugs as of 2024, including the first innovative drug, EGFR-TKI Alectinib (brand name: Kaimena®), and ALK inhibitor Ensartinib (brand name: Beimana®) among others[39]. - The company has a robust revenue growth and cash flow driven by a "R&D - commercialization - reinvestment" cycle, ensuring orderly advancement of its R&D pipeline[40]. - The company’s R&D investment for the year reached 71,717.78 million yuan, accounting for 24.80% of total revenue[79]. - The company focuses on innovative drug development, having successfully developed 5 new drugs and established a robust product pipeline[69]. - The company has several ongoing clinical trials, including BPI-520105 for EGFR mutation-positive solid tumors, currently in Phase I[110]. - The company is advancing multiple clinical trials, including Balstilimab and Zalifrelimab for cervical cancer, both in Phase II[108]. Market and Industry Trends - The pharmaceutical industry in China saw a 3.4% increase in added value for large-scale pharmaceutical enterprises in 2024, indicating a recovery trend[26]. - The government has implemented various policies to support the pharmaceutical industry, including reforms in drug procurement and healthcare insurance, which are expected to enhance industry growth[27]. - The market share of innovative drugs in China's core hospitals increased from 21% in 2015 to 29% in 2024, indicating significant growth momentum[30]. - The proportion of First-in-Class new drugs rose from 12% in 2020 to 35% in 2024, reflecting a shift towards differentiated targets and innovative technologies[33]. - The global pharmaceutical market is projected to reach $1.7667 trillion by 2026 and $2.0694 trillion by 2030, presenting substantial opportunities for domestic pharmaceutical companies[35]. - The biopharmaceutical industry in China is transitioning from "follower" to "leader," with significant growth in targeted therapy and immunotherapy sectors[143]. Corporate Governance and Management - The company has a commitment to ensuring the accuracy and completeness of its financial reports, as stated by its management[5]. - The company has a dedicated investor relations team to facilitate communication with stakeholders[13]. - The company emphasizes talent development, with nearly 40 PhDs and several recognized as national and provincial leading talents, aiming to boost organizational efficiency and innovation[86]. - The company has established a complete business system with independent operations in research, production, and sales, ensuring no competition or unfair transactions with the controlling shareholder[173]. - The company maintains independent financial operations, with a dedicated finance department and no shared bank accounts with the controlling shareholder[175]. - The company has a robust governance structure that aligns with legal requirements, ensuring effective decision-making and risk management[172]. - The board of directors consists of 11 members, including 4 independent directors, and held 8 meetings, ensuring compliance with legal procedures[166]. Product Development and Approvals - The application for the first-line indication of Beimana was approved by the FDA in December 2024, with the EMA submission process officially initiated[40]. - The company’s drug "Kai Meina" is the first domestically developed small molecule oral EGFR-TKI lung cancer targeted therapy approved for postoperative adjuvant indications[46]. - "Fu Meina," a new drug for advanced renal cell carcinoma, achieved a median progression-free survival (PFS) of 10 months and an overall survival (OS) of 30.4 months in combination therapy[45]. - The company’s product "Bei Meina" is the first Chinese original drug included in the NCCN guidelines for ALK-positive advanced NSCLC, with a median progression-free survival of 41.5 months in the overall population[44]. - The company’s product Beimingna was included in the National Medical Insurance Directory, enhancing its market position[76]. - The company’s product, Saimina, has been included in the National Basic Medical Insurance Drug List for 2024, with sales of Kaimina and Beimina accounting for over 10% of the company's main business revenue[97]. Strategic Initiatives and Future Plans - The company plans to distribute a cash dividend of 2 RMB per 10 shares to all shareholders, based on a total of 418,485,885 shares[6]. - The company emphasizes the importance of risk awareness regarding market competition and new drug development in its future plans[6]. - The company plans to explore combination therapies with "Kai Meina" to expand patient populations and enhance clinical value[49]. - The company is actively expanding its product pipeline, with multiple innovative drug applications approved, including BPI-520105 and BPI-221351[79]. - The company is focusing on expanding its manufacturing capacity to support stable production and meet market demand[96]. - The company plans to use up to RMB 250 million of idle raised funds for temporary working capital, with a remaining balance of RMB 180 million as of December 31, 2024[132]. - The company aims to enhance market expansion and brand strengthening with the launch of products like Kangmeina and He Yuan's albumin project, focusing on seven products[146]. Risk Management and Challenges - The company acknowledges the high investment, long cycle, and low success rate associated with new drug development, which poses risks throughout the clinical development process[152]. - The company recognizes the risk of losing core technical personnel, which could hinder new drug development and market expansion efforts[154]. - To mitigate competition risks, the company plans to strengthen product market positioning, implement differentiated competition strategies, and enhance patient education through new media[151]. - The company is adapting to industry policy changes and focusing on effective participation in centralized procurement to mitigate risks related to market access and operational costs[156].

贝达药业（300558）公告，2024年营业收入28.92亿元，同比增长17.74%。归属于上市公司股东的净利 润4.03亿元，同比增长15.67%。基本每股收益0.96元/股，同比增长15.66%。公司拟以4.18亿股为基数， 向全体股东每10股派发现金红利2元(含税)，送红股0股(含税)，以资本公积金向全体股东每10股转增0 股。 ...

消息面上，4月13日，中国人民银行发布了主要金融数据，首季社会融资规模增量超15万亿元、新增贷 款9.78万亿元、3月末广义货币M2余额同比增长7%。数据展现着金融对实体经济保持稳固支持，也折射 出实体经济需求持续回暖。此外，一季度全国工程机械平均开工率为44.67%，较去年同期增幅为 1.62%，折射出一季度中国经济平稳起步。 4月14日，A股市场主要指数高开后午后有所回落，大盘蓝筹风格整体走势平稳，A500和A50指数通过 行业均衡配置和聚焦优质龙头，契合资金关注主线。 相关产品：A500ETF（159339）、A50ETF基金（159592） MACD金叉信号形成，这些股涨势不错！ A股核心资产代表，"A股的标普500"：A500ETF（159339）跟踪的A500指数以不足A股市场10%的成份 股数量，覆盖全市场63%的总营收和70%的总净利润，或是大家长期布局我国资本市场高质量发展趋势 的有力工具。 各行业超级龙头，"漂亮50"：A50ETF基金（159592）跟踪的A50指数布局各行业超大市值龙头股，这 些绩优大白马在供给侧改革的趋势下受益于市场集中度提升，在业绩披露期或更受资金青睐。 华泰证券认 ...

证券研究报告 | 医药生物 | 2025年4月12日 www.hczq.com 华创医药投资观点&研究专题周周谈·第121期 海外CXO 2024财报总结 本周周专题联系人：万梦蝶 | 华创医药团队： | | | --- | --- | | 首席分析师 郑辰 | 执业编号：S0360520110002 邮箱：zhengchen@hcyjs.com | | 联席首席分析师 刘浩 | 执业编号: S0360520120002 邮箱: liuhao@hcyjs.com | | 医疗器械组组长 李婵娟 | 执业编号：S0360520110004 邮箱：lichanjuan@hcyjs.com | | 中药和流通组组长 高初蕾 | 执业编号：S0360524070002 邮箱：gaochulei@hcyjs.com | | 分析师 万梦蝶 | 执业编号: S0360523080008 邮箱: wanmengdie@hcyjs.com | | 分析师 王宏雨 | 执业编号：S0360523080006 邮箱：wanghongyu@hcyjs.com | | 分析师 朱珂琛 | 执业编号：S0360524070007 邮箱 ...

Core Viewpoint - BeiGene has decided to terminate the clinical development of its TIGIT inhibitor, ociperlimab, after an independent data monitoring committee recommended stopping the ongoing Phase III AdvanTIG-302 trial due to the likelihood of not meeting the primary endpoint of overall survival [1][2]. Group 1: Company Actions - BeiGene has invested a total of 2.09 billion RMB (approximately 20.9 million) in the ociperlimab project as of the first half of 2024 [1][2]. - The decision to terminate the trial was made after careful consideration of the efficacy and safety data, with no new safety signals identified [2]. - Following the termination of the trial, BeiGene will focus its resources on more promising candidates with clinical differentiation [2]. Group 2: Collaboration and Financials - In December 2021, BeiGene entered into an option agreement with Novartis, granting Novartis exclusive rights to develop, manufacture, and commercialize ociperlimab, for which BeiGene received a $300 million upfront payment [3]. - In July 2024, BeiGene and Novartis signed a termination agreement, allowing BeiGene to regain all global rights to ociperlimab [3]. - As of the end of 2023, BeiGene reported collaboration revenue related to the ociperlimab agreement of $192 million (approximately 1.41 billion RMB), which is expected to decrease to $18.26 million (approximately 134 million RMB) by the end of 2024 [4]. Group 3: Industry Context - The TIGIT pathway has been a popular target in cancer treatment development, with multiple pharmaceutical companies, including Roche, Bristol-Myers Squibb, and Merck, also halting their TIGIT antibody research due to unsatisfactory results [5][6]. - Despite the setbacks, some companies, such as AstraZeneca and GSK, continue to pursue TIGIT-related therapies, with ongoing clinical trials for their respective candidates [6].

Investment Rating - The report maintains a "Buy" rating for the company [5] Core Views - The company is expected to achieve an EPS of 1.06/1.17 CNY for 2025-26, with a new forecast of 1.42 CNY for 2027. The target price is set at 56.18 CNY based on a PE ratio of 53 for 2025 [2] - The company reported a significant revenue increase of 22.63% year-on-year for 2024, reaching 27.985 billion CNY, and a net profit increase of 47.28%, totaling 6.337 billion CNY [9] - The company is actively advancing its internationalization efforts, with several products receiving FDA approval and significant licensing agreements contributing to revenue growth [9] Financial Information Summary - Revenue (in million CNY): - 2023A: 22,820 - 2024A: 27,985 (22.6% YoY growth) - 2025E: 31,684 (13.2% YoY growth) - 2026E: 35,553 (12.2% YoY growth) - 2027E: 40,900 (15.0% YoY growth) [4] - Net Profit (in million CNY): - 2023A: 4,302 - 2024A: 6,337 (47.3% YoY growth) - 2025E: 6,759 (6.7% YoY growth) - 2026E: 7,477 (10.6% YoY growth) - 2027E: 9,060 (21.2% YoY growth) [4] - EPS (in CNY): - 2023A: 0.67 - 2024A: 0.99 - 2025E: 1.06 - 2026E: 1.17 - 2027E: 1.42 [4] - Gross Margin: - 2023A: 84.6% - 2024A: 86.2% - 2025E: 84.5% - 2026E: 84.9% - 2027E: 85.4% [4] - Net Margin: - 2023A: 18.9% - 2024A: 22.6% - 2025E: 21.3% - 2026E: 21.0% - 2027E: 22.2% [4]

Investment Rating - The report assigns an "Overweight" rating to the pharmaceutical and biotechnology industry, indicating that the industry index is expected to outperform the CSI 300 index by 10% or more over the next six months [35]. Core Insights - The pharmaceutical and biotechnology sector showed a 1.20% increase in performance from March 31 to April 3, ranking third among 31 industries and outperforming the CSI 300 index by 2.57 percentage points [11][16]. - Year-to-date, the sector has risen by 4.77%, ranking seventh among 31 industries and surpassing the CSI 300 index by 6.64 percentage points [16]. - The current PE valuation for the pharmaceutical and biotechnology sector stands at 27.2 times, which is at a historically low level, with a 130% premium compared to the CSI 300 index [20]. Market Performance - The top three sub-sectors in terms of growth last week were chemical pharmaceuticals (3.45%), traditional Chinese medicine II (1.53%), and pharmaceutical commerce (1.48%) [11]. - A total of 344 stocks (72.57% of the sector) experienced price increases last week, with the top five performers being Duorui Pharmaceutical (56.32%), Weisi Medical (31.80%), Hasanlian (31.15%), Rundu Co. (27.01%), and Shengnuo Biological (21.54%) [25][26]. Industry News - On April 4, the Ministry of Commerce announced investigations into the competitiveness of imported medical CT tubes and initiated anti-dumping investigations against imports from the United States and India [27][30]. - The investigations will assess the impact of these imports on the domestic industry and its competitiveness, covering the period from January 1, 2024, to December 31, 2024, for dumping and from January 1, 2022, to December 31, 2024, for industry damage [29][30]. Investment Recommendations - The report suggests focusing on sectors such as innovative drugs, medical services, and domestic market-oriented businesses, which are less affected by trade frictions [31]. - It highlights the potential for accelerated domestic substitution in high-end medical equipment and blood products due to ongoing tariff disputes [31]. - Recommended stocks include Beida Pharmaceutical, Laobaixing, Lingrui Pharmaceutical, Huaxia Eye Hospital, and Boya Biological, with additional stocks to watch being Tebao Biological, Kelun Pharmaceutical, International Medicine, Kaili Medical, and Nuotai Biological [32].